Biotech Values

[vinmantoo]

People don't want to face the facts they we don't have an unlimited amount of money and the idiots on Wall Street fuel the fire with even more unrealistic comments. I read where one analyst was talking about Provenge and saying DNDN wasn't charging enough because some drugs cost $200K to $400K per patient. Now those drugs are orphan drugs and the high price was set to enable companies to keep making drugs for a very small patient population. It is absurd and a mark of the delusional greed that fuels Wall Street to use that type of pricing for a large patient population.

Now if the US government decides that the benefits shown by DNDN isn't worth the $93K price tag, DNDN will have to lower the price and accept less profits to get Medicare approval. What a shame.